AstraZeneca’s Lynparza shown to put brakes on ovarian cancer

An AstraZeneca drug that blocks a cancer cell's ability to repair its genetic code greatly reduced the risk of ovarian cancer worsening in a phase III trial, underpinning its lead against two U.S. rivals in the same class.
Original Article